An Analysis of Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

An Analysis of Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market

Attention Deficit Hyperactivity Disorder (ADHD) is a psychiatric condition which is initially evident in the childhood. It is the subject of active scientific investigation and great clinical interest. The impairments of this syndrome are likely to remain even in adolescence and adulthood. It is a biological condition which makes it hard for the children to sit calm and concentrate. The disorder is not a result of bad parenting or disobedient behavior of the kid. The area of the brain which controls the ability to focus will be very slow and less active in the children who have ADHD.

Over time, the symptoms of ADHD may change, but it is a lifelong disorder. Though the disorder is not curable, there are many practically effective strategies and treatment options to handle the symptoms and reduce them. Medical research opines that kids in the age group of 4 to 17 are diagnosed with ADHD. The researchers didn’t know the exact cause of this syndrome yet but identified that it is a brain-based biological condition. The possible causes of this are genes and heredity, differences in the brain, structure etc.

The areas or activities that are significantly affected by ADHD include social skills, self-control, organization, planning, learning, thinking, focussing and understanding. The treatment demands collaborative effort continuously. Though it doesn’t help in reducing the disease but assists in normalizing the brain activity. TheGlobal ADHD therapeutics market might soon reach US$ 12.43 billion by 2021.

Request free sample report at https://www.marketdataforecast.com/market-reports/global-attention-deficit-hyperactivity-disorder-therapeutics-market-304/request-sample

Outlook of ADHD Therapeutics Market – Rife with Unmet needs

The revenue from global ADHD therapeutics market is estimated to expand at a CAGR of 9% during the forecast period of 2016 – 2021. The drug types are divided into stimulants and non-stimulants. The drugLisdexamfetamine dimesylate is projected to mark the highest CAGR in the coming decades. The longer effectiveness and easier availability of drugs contribute to the growth of this market. The segment under Amphetamine recorded the highest growth with stimulants are emerging as the most preferred drug type in the global market.The market for Attention Deficit Hyperactivity Disorder (ADHD) therapeutics across the seven developed economies such as U.S., France, Germany, Italy, Spain, U.K and Japan is expected is rise due to changing food habits, genetic factors and environmental influences.

North America and Europe markets are estimated to contribute the four-fifths share to the global market by the end of 2021. Sweden’s market is also ramping up to cross the benchmarks along with United States of America.Some of the crucial companies in the ADHD therapeutic global market are Eli Lilly and Company, Shire PLC, Johnson & Johnson (J&J), Pfizer, GlaxoSmithKline PLC, Hisamitsu Pharmaceutical Co., Inc., UCBD S.A., Vyvanse, etc.

Some two decades back, thirty-one countries adopted the usage of ADHD medications, and the number went up to 55 by 2003. Moving to the global expenditures in ADHD medication market, U.S. depicted a drastic increase with the highest share of 36% of the global attention deficit hyperactivity disorder or ADHD. The prevalence of ADHD is 5% to 8% in U.S. children, and Canada has also had substantial shares in ADHD medication share in the global ADHD therapeutic medication market. The ADHD is now recognized globally as a disease that is rising exponentially from approximately 15 million cases in 2013 that may rise to over 18 million by the end of 2020 even though the diagnosis rate outside United States of America are low due to considerable scepticism about the disease.

Benefits of taking ADHD Medications – Reduces the symptoms

However, medication cannot cure ADH as these medications only help to control and manage the challenging symptoms like inability to concentrate, lack of impulse control, low frustration tolerance, etc of the patients suffering from ADHD. Here are some of the notable benefits of taking therapies and medications of ADHD:

Improves academic performance
Gains self-esteem
Enhances the family functioning
Decreased risk of depression and anxiety

The secondary advantages of the medications are the symptoms such as suppression of hyper emotions and reduced crimes. Medications alone are not a panacea, and the comprehensive treatment plan should also include behavioral therapy, healthy lifestyle changes, and appropriate educational interventions.

 
This press release has been viewed 86 times on PR Buzz.